AC
Insider
Adam R Craig
Executive ChairmanAdam R Craig (Executive Chairman) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in X4 Pharmaceuticals, Inc. (XFOR). Across 1 priced purchase filing, the average 21-session return was +19.7% from execution and +1.9% from disclosure (delay-adjusted; derived). The largest single filing was $250K of XFOR (86,206 sh × $2.90, as filed), executed Oct 23 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+19.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+1.9%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$461K
shares × price, as filed
Last traded
Aug 12
Filed Aug 13
Median ADV $3.2M across their filed names
Open performance→Volume by month
Buys $250K
Sells $211K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
XFORRecent filings
XFORSALE
X4 Pharmaceuticals, Inc.
View filing →
$211K47,436 sh × $4.44
Exec Aug 12
Filed Aug 13 · 4:10 PM ET XFORPURCHASE X4 Pharmaceuticals, Inc. View filing → $250K
86,206 sh × $2.90
Exec Oct 23 2025
Filed Oct 27 2025 · 6:40 PM ET